SpyGlass Pharma: Vensana Capital I distributes 331K shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
SpyGlass Pharma, Inc. (SGP) reported share movements involving Vensana Capital I, L.P. and Vensana Capital I GP, LLC in a Form 4 filed by director Kirk G. Nielsen. On November 16, 2026, Vensana Capital I distributed 331,036 shares pro rata to its partners without additional consideration. Vensana Capital I GP received 8,646 shares in an in-kind distribution and distributed 8,634 shares pro rata to its members without consideration. The footnotes describe the distributions as not purchases or sales and say Kirk G. Nielsen disclaims beneficial ownership, except to the extent of his pecuniary interest.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Other | Common Stock F1, F2 | 331,036 | $0.00 | $0.00 |
| Other | Common Stock F3, F4 | 8,646 | $0.00 | $0.00 |
| Other | Common Stock F5, F4 | 8,634 | $0.00 | $0.00 |
Footnotes (5)
- F1. Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Vensana Capital I, L.P. ("Vensana I") to its partners.
- F2. These shares are held directly by Vensana I. Vensana Capital I GP, LLC ("Vensana GP I") is the general partner of Vensana I. Each of the Reporting Person, a member of the Issuer's board of directors, and Peter Justin Klein (the "GP I Managing Directors") is a managing director of Vensana GP I. Each of Vensana GP I and the GP I Managing Directors, in their capacities with respect to Vensana GP I, may be deemed to share voting, investment and dispositive power with respect to the shares held by Vensana I. Each of Vensana GP I and the GP I Managing Directors disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of Vensana GP I or the GP I Managing Directors is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
- F3. Represents a change in the form of ownership of Vensana GP I by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Vensana I.
- F4. Shares are held by Vensana GP I. Each of the GP I Managing Directors is a managing director of Vensana GP I. Each of the GP I Managing Directors, in their capacities with respect to Vensana GP I, may be deemed to share voting, investment and dispositive power with respect to the shares held by Vensana GP I. Each of the GP I Managing Directors disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the GP I Managing Directors is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
- F5. Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Vensana GP I to its members.
Key Figures
Key Terms
pro-rata distribution financial
in-kind distribution financial
beneficial ownership regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.